BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Acitretin and teratogenicity: Compliance with safety measures in women of childbearing potential

Active substance: acitretin

On a European level it is currently being discussed that the 2-year period of pregnancy prevention in patients of childbearing potential is possibly not sufficient and must therefore be extended to 3 years after end of treatment.

To the risk information - full text (available in German only)